PODD vs TNDM: How Insulet Corporation and Tandem Diabetes Care Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: PODD is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. PODD and TNDM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined PODD and TNDM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Insulet Corporation sells one thing extremely well. The Omnipod is a small adhesive pod worn on the body that holds insulin and delivers it without tubing, controlled by a phone app or a handheld. The current generation, Omnipod 5, is an automated insulin delivery system: it reads a continuous glucose monitor (Dexcom G7 or Abbott's FreeStyle Libre) and adjusts basal insulin automatically. The pods are disposable and replaced every three days, so the business is a classic razor-and-blade model where each new user converts into a predictable multi-year consumable stream. Insulet also distributes most of its US volume through the pharmacy channel rather than durable medical equipment, which lowers the friction of getting a patient started and has been a structural advantage over tubed competitors. A small drug delivery segment supplies pod technology to a pharmaceutical partner, but it is under ~2% of revenue and shrinking by design.

Full PODD guide

Tandem Diabetes Care designs, makes, and sells insulin pumps for people with diabetes. Its flagship products are the t:slim X2 pump and the much smaller Tandem Mobi system, both running Control-IQ+ automated insulin delivery software that reads data from a continuous glucose monitor (CGM) and automatically adjusts insulin dosing. The business works on a razor-and-blade model: Tandem earns an up-front sale when a customer adopts a pump, then recurring revenue from the disposable cartridges, infusion sets, and other supplies that customer buys for years afterward. Pumps integrate with third-party CGMs from Dexcom (G6/G7) and Abbott (FreeStyle Libre), which Tandem does not make itself.

Full TNDM guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• PODD drivers: Installed base compounding through pods; International expansion.
• TNDM drivers: Recurring supplies and a growing installed base; Tandem Mobi and Control-IQ+ product cycle.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Type 2 retention is the live risk and the reason the shares derated: if attrition inside the first 90 days does not improve, the largest piece of the long-term growth story shrinks, and management's preliminary 2027 view of only mid-teens constant-currency growth already assumes no benefit from the fixes. For TNDM, competition is the central risk: Insulet's tubeless Omnipod 5 is the fastest-growing system in the market, Medtronic remains a large incumbent, and newer entrants like Beta Bionics' iLet and Sequel's twiist add pressure, all of which can squeeze Tandem's pricing and pump share.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick PODD if you believe its drivers more; TNDM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the PODD and TNDM guides.

PODD. Insulet guided full-year 2026 revenue to roughly $3.2-3.3 billion with constant-currency growth of ~20-22%, trimmed from ~21-23%, and cut US Omnipod growth to ~17-19% while raising international to ~30-32%. The cut was small in dollars but changed the narrative, and the shares fell about 20% on August 5, 2026 to around $133 against a 52-week high of ~$355. At roughly 19x forward earnings the stock now prices in materially slower growth than it did a year earlier.

TNDM. Tandem is best read as a growth medtech rather than a mature, profitable company. The model is razor-and-blade: pumps are sold (sometimes at thin margin) to build an installed base, and the recurring supplies that base buys over the following years drive higher-margin revenue. Heavy spending on research, sales, and manufacturing scale is why the company has not been consistently profitable on a GAAP basis even at roughly $1 billion in sales, so investors tend to watch pump shipments, installed-base growth, gross margin, and the path to positive adjusted EBITDA rather than a simple P/E ratio.

Headline figures (approximate, August 2026): PODD shows revenue (ttm) ~$3.05B, q2 2026 revenue ~$802M, up ~23% year over year, adjusted gross margin (q2 2026) ~72.9%, net income / eps (ttm, gaap) ~$375M / ~$5.35; TNDM shows fy2025 revenue ~$1.0 billion worldwide, pump shipments International >40,000 for FY2025; ~29,000 worldwide in Q1 2026, u.s. installed base ~324,000 customers (12/31/25), gross margin (non-gaap) ~54% FY2025; ~58% Q4 2025.

PODD and TNDM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined PODD and TNDM exposure against your real portfolio. It is not an investment adviser.